ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

NCI CTEP Approved Trials For the Month of August

August 30, 2013

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

December 5, 2014

Gavel Changes Hands At NCAB, Korn advises New Members On Role

February 8, 1991

Pain Relievers Protect Against Breast Cancer

April 25, 2003

MSKCC In Outreach Agreement With Phelps

December 1, 1995

Women Surgeons: We Need Answers On Tamoxifin Now

May 13, 1994